India’s first nasal vaccine: 10 points to know
It is BBV154, novel adenovirus vectored, intranasal vaccine for COVID-19
An intranasal vaccine stimulates a broad immune response – neutralizing IgG, mucosal IgA, and T cell responses, says Bharat Biotech.
Coronavirus vaccination: With the looming threat of the new variant in India, what should people do who haven’t taken their COVID booster dose
It is effective in blocking the infection and transmission as it initiates an immune response at the infection site which is the nasal mucosa.
In this, if infected the immune system prevents the coronavirus infection in both upper and lower respiratory tracts.
It is non-invasive and needle free
Cases of BF.7 variant responsible for COVID surge in China, detected in India: Know the top symptoms
It can be easily administered unlike the other vaccines
There is complete elimination of injuries and infections associated with the needles and syringes
It is highly suitable for kids
This vaccine is expected to be administered to those above 18 years of age. Details of the pricing and availability will soon be updated in the CoWIN portal.
iNCOVACC had received approval from the Drugs Controller General of India under Restricted Use in Emergency Situation for ages 18 and above on September 6.
As of now Bharat Biotech’s COVAXIN, Serum Institute’s COVISHIELD are mostly used in the country.
In view of the COVID situation in China, Indian government has geared up preventive measures against the infection. Four cases of the BF.7 variant which is the dominant strain in the country have been found in India. The Center has released guidelines. All travellers should preferably be fully vaccinated as per the approved primary schedule of vaccination in their country, it said.
It has also made wearing of masks and social distancing compulsory in flight and at entry and exit points of airports.
